Skip To Main Content
Stanley E Althof on Muck Rack

Stanley E Althof

As seen in: Color Research & Application, Women's Health (SAGE Journal), Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Stanley E Althof’s profile

Articles by Stanley E Althof

Erectile Dysfunction is a Modifiable Risk Factor for Major Depressive Disorder: Analysis of a Federated Research Network

|
By Sirpi Nackeeran, Jesse Ory, Stanley E Althof, Amoghavarsha Havanur
| jsm.jsexmed.org
Abstract Background Erectile dysfunction is one of many conditions associated with depression, but few studies exist to establish the risk of major depressive disorder (MDD) in the large population of men with erectile dysfunction, and it is unclear whether erectile dysfunction (ED) treatment is associated with decreased rates of MDD.
Open in Who Shared Issue with article?

Clinically important difference on the Erectile Dysfunction Inventory of Treatment Satisfaction questionnaire in patients with erectile dysfunction

|
By Joseph C Cappelleri, Li-Jung Tseng, Vera Stecher, Stanley E Althof
| Color Research & Application Verified
To determine what constitutes a clinically important difference (CID) on the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS), an 11-item validated questionnaire assessing treatment satisfaction used in clinical trials for patients with erectile dysfunction (ED). Erectile Dysfunction Inventory of Treatment Satisfaction data were evaluated from a double-blind, fixed-dose trial of 279 men aged 18-65 years with ED who were treated with sildenafil 50 or 100 mg or placebo.
Open in Who Shared Issue with article?

Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial

|
By Anita H. Clayton, Stanley E Althof, Sheryl Kingsberg, Leonard R DeRogatis, Robin Kroll
| Future Medicine Verified
Aim: Evaluate efficacy/safety of bremelanotide (BMT), a melanocortin-receptor-4 agonist, to treat female sexual dysfunctions in premenopausal women. Methods: Patients randomized to receive placebo or BMT 0.75, 1.25 or 1.75 mg self-administered subcutaneously, as desired, over 12 weeks. Primary end point was change in satisfying sexual events/month. Secondary end points included total score changes on female sexual function index and female sexual distress scale-desire/arousal/orgasm.
Open in Who Shared Issue with article?

Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial

|
By Anita H. Clayton, Stanley E Althof, Sheryl Kingsberg, Leonard R DeRogatis
| Women's Health (SAGE Journal) Verified
This study was funded by Palatin Technologies, Inc.
Open in Who Shared Issue with article?
Show More